Rheumatology/Infectious Diseases
Tocilizumab
This activity examines the wide-ranging applications of tocilizumab, a humanized monoclonal antibody approved by the FDA for managing rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (PJIA), systemic juvenile idiopathic arthritis (SJIA), and COVID-19 pneumonia. The program elucidates the intricate mechanisms of action underlying tocilizumab's efficacy, detailing its authorized uses across diverse patient populations. Emphasis is placed on the int
v1 · Reviewed Nov 7, 2026 by Automated Clinical Reviewer (Strict Verbatim v1)
- Cytokine release syndrome (Severe or life-threatening, CAR T-Cell therapy)
- Patients ≥2 years of age with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS)
- The Infectious Diseases Society of America recommends treatment with tocilizumab and a glucocorticoid (eg, dexamethasone) in hospitalized adults with declining blood oxygen saturation levels (eg, pulse oximetry ≤94%) and patients on mechanical ventilation or oxygenation with signs of increased systemic inflammation (eg, C-reactive protein).
- The National Institutes of Health recommends treatment with tocilizumab and a glucocorticoid (eg, dexamethasone) in hospitalized patients with rapidly declining pulmonary function.
- Tocilizumab carries an FDA box warning for an increased risk of serious infections.
- When the absolute neutrophil count (ANC) <2,000/mm3, platelet count <100,000/mm3, alanine aminotransferase (ALT) or aspartate (AST) >1.5 times the upper limit of normal (ULN), the manufacturer recommends that tocilizumab not be initially given to patients with rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, or systemic sclerosis-associated interstitial lung disease.
- The Infectious Diseases Society of America recommends treatment with tocilizumab and a glucocorticoid (eg, dexamethasone) in hospitalized adults with declining blood oxygen saturation levels (eg, pulse oximetry ≤94%) and patients on mechanical ventilation or oxygenation with signs of increased systemic inflammation (eg, C-reactive protein).
- Cytokine release syndrome (Severe or life-threatening, CAR T-Cell therapy)
- Giant cell arteritis
- Rheumatoid arthritis (Moderate to severe)
- Systemic sclerosis-associated interstitial lung disease (SSc-ILD)
- Polyarticular juvenile idiopathic arthritis (PJIA)
- Systemic juvenile idiopathic arthritis (SJIA)
- COVID-19
Tocilizumab
IV
- Adult
- >30 kg: 8 mg/kg IV, maximum 800 mg/dose
- Renal
- Not specified in source
- Duration
- may be used as monotherapy or in combination with a glucocorticoid. If no clinical improvement occurs after the first dose, 3 additional doses may be administered in at least 8-hour intervals.
Tocilizumab
SQ
- Adult
- 162 mg SQ once weekly
- Renal
- Not specified in source
- Duration
- combined with a tapering dose of a glucocorticoid.
Tocilizumab
IV
- Adult
- 6 mg/kg/dose IV every 4 weeks; maximum 600 mg/dose
- Renal
- Not specified in source
- Duration
- in combination with a glucocorticoid.
Tocilizumab
IV
- Adult
- 4 mg/kg IV once every 4 weeks may increase to 8 mg/kg IV once every 4 weeks, with a maximum dosage of 800 mg/dose
- Renal
- Not specified in source
- Duration
- monotherapy, or with methotrexate or a nonbiologic DMARD.
Tocilizumab
SQ
- Adult
- >100 kg: 162 mg SQ once every week, <100 kg, 162 mg SQ once every other week
- Renal
- Not specified in source
- Duration
- monotherapy or with methotrexate or a nonbiologic DMARD.
Tocilizumab
SQ
- Adult
- 162 mg SQ once every week
- Renal
- Not specified in source
- Duration
- Not specified in source
Tocilizumab
IV
- Adult
- <30 kg: 10 mg/kg IV once every 4 weeks; >30 kg: 8 mg/kg IV once every 4 weeks, maximum 800 mg/dose.
- Renal
- Not specified in source
- Duration
- Not specified in source
Tocilizumab
SQ
- Adult
- <30 kg: 162 mg SQ once every 3 weeks; >30 kg: 162 mg SQ once every 2 weeks.
- Renal
- Not specified in source
- Duration
- Not specified in source
Tocilizumab
IV
- Adult
- <30 kg: 12 mg/kg IV once every 2 weeks; >30 kg: 8 mg/kg IV once every 2 weeks.
- Renal
- Not specified in source
- Duration
- Not specified in source
Tocilizumab
SQ
- Adult
- <30 kg: 162 mg SQ once every 2 weeks; >30 kg: 162 mg SQ once every week.
- Renal
- Not specified in source
- Duration
- Not specified in source
Tocilizumab
IV
- Adult
- 8 mg/kg/dose IV for a single dose.
- Renal
- Not specified in source
- Duration
- Not specified in source
- Tocilizumab is contraindicated with live vaccines and with talimogene laherparepvec.
- The drug should not be used concomitantly with many other immunosuppressive monoclonal antibodies due to the risk of severe infection.
- Tocilizumab may also decrease the effectiveness of oral hormonal contraceptives.
- A contraindication tocilizumab therapy is a hypersensitivity reaction to the tocilizumab dosage form.
- Some of the tocilizumab dosage forms may contain polysorbate 80. Polysorbate 80 can cause a delayed hypersensitive reaction in allergic patients. In premature infants with a hypersensitivity reaction, it can cause damage to the lungs, liver, and kidneys, as well as cause thrombocytopenia and ascites.
- For COVID-19: avoid use in patients with baseline AST/ALT >10 times the upper normal limit.
- No adjustment is necessary for patients with CrCl >30. For CrCl <30, dose adjustments are undefined.
- Clinicians should weigh the risk vs benefit in pregnant patients. Insufficient human data is available, but there is a possible risk of embryo-fetal toxicity based on animal studies.
- Tocilizumab can be used while breastfeeding; no human data exists, but based on drug characteristics, there is no risk of infant harm. There is no human data regarding the effects on milk production.
- For RA, giant cell arteritis, or SSc-ILD: Patients should have the following baseline tests: hepatitis B serology, including HBsAg, TB test, AST/ALT, alkaline phosphatase, and total bilirubin every 4 to 8 weeks for 6 months, then every 3 months.
- They should also have a baseline ANC and platelets at 4 to 8 weeks, then every 3 months.
- Finally, a lipid panel should be performed 4 to 8 weeks following treatment initiation.
- For PJIA: Patients should have the following baseline tests: hepatitis B serology, including HBsAg, TB test, AST/ALT, alkaline phosphatase, total bilirubin, ANC, and platelets, then at the 2nd infusion, then every 4 to 8 weeks.
- For SJIA: Patients should have the following baseline tests: hepatitis B serology, including HBsAg, TB test, AST/ALT, alkaline phosphatase, total bilirubin, ANC, and platelets, then at the 2nd infusion, then every 2 to 4 weeks.
- For COVID-19: Patients should have AST/ALT, ANC, and platelets at baseline and during treatment.
- The healthcare team should monitor the patient for signs or symptoms of infection, eg, tuberculosis, candidiasis, etc.
- The manufacturer recommends discontinuing tocilizumab therapy if the ALT or AST becomes more than 5 times the ULN, ANC <500 cells/mm3, or platelets <50,000 cells/mm3.
- reviewTocilizumab. StatPearls [Internet] — Charles V. Preuss, Fatima Anjum — StatPearls Publishing, 2024
Decision support only. Verify against local protocols and current labeling. Source: www.ncbi.nlm.nih.gov